Among them, we showed that the anthracycline antibiotics and classic cancer chemotherapeutics (i) doxorubicin, (ii) daunorubicin, and (iii) idarubicin are predicted to be able to reverse TOP2A upregulation. The gene discussed is TOP2A; the disease is cancer.